|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||49.4800 - 50.0100|
|52 Week Range||43.4100 - 51.7370|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
On April 27, 2017, Novartis was trading at a forward PE multiple of ~15.8x. The industry currently trades at a forward PE multiple of ~15.9x.
On April 25, 2017, Novartis (NVS) reported a 2.0% rise in revenues at constant currencies for 1Q17. Revenues fell due to a 3.0% negative impact of foreign exchange.
GlaxoSmithKline’s (GSK) stock price fell nearly 5.5% over the last 12 months and have risen ~5.9% in 2017 year-to-date.
GlaxoSmithKline is set to release its 1Q17 earnings on April 26, 2017. Analysts estimate GSK's earnings per share to reach 0.25 pounds for 1Q17.
GlaxoSmithKline (GSK) is estimated to report EPS of 111.01 pence on revenues of ~30.0 billion pounds in 2017, 7.6% growth compared to 2016 revenues.
GlaxoSmithKline’s (GSK) Pharmaceuticals segment fell substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.
Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.
On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years' multiple range, JNJ’s current valuation is neither high nor low.